Middle East And Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (2024 - 2029)

The Middle East and Africa Dipeptide Peptidase 4 Inhibitors market is projected to experience growth over the forecast period, driven by the increasing prevalence of type 2 diabetes in the region. The market's expansion is influenced by the rising obesity rates and genetic predispositions that contribute to the high diabetes incidence. The COVID-19 pandemic has further underscored the importance of DPP-4 inhibitors, as they offer therapeutic benefits for diabetic patients, potentially reducing severe COVID-19 complications. These factors collectively contribute to the anticipated growth in the market size during the analysis period.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Hyperglycemics Research MEA DPP-4 Inhibitors Industry Market Size

Market Size of Middle East And Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry

Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Summary
Study Period 2019- 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 758.32 Million
Market Size (2029) USD 893.21 Million
CAGR (2024 - 2029) 3.60 %

Major Players

Middle East And Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Major Players

*Disclaimer: Major Players sorted in no particular order

Middle East and Africa Dipeptide Peptidase 4 (DPP-4) inhibitors Market Analysis

The Middle East And Africa Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 758.32 million in 2024, and is expected to reach USD 893.21 million by 2029, growing at a CAGR of 3.60% during the forecast period (2024-2029).

The COVID-19 pandemic positively impacted the Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.

The diabetic prevalence is high in countries in the Middle East and African region. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, nearly 10% of the population is living with diabetes. Diabetic patients in the Middle East and African region mainly suffer from Type-2 diabetes, accounting for nearly 90% of the total diabetic population in 2021.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Middle East and Africa Dipeptide Peptidase 4 (DPP-4) inhibitors Industry Segmentation

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a pharmacological class of drugs for treating Type 2 diabetes. They help to control glycemia by increasing the levels of active incretins. The Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is segmented into drugs (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), Galvus (Vildagliptin), and Others) and Geography. The report offers the value (in USD) and volume (in Units) for the above segments. Further, the report will cover a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.

Drug
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Other Drugs
Geography
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region Or Segment?
Customize Now

Middle East And Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size Summary

The Middle East and Africa dipeptidyl peptidase 4 (DPP-4) inhibitors market is poised for growth, driven by the increasing prevalence of type 2 diabetes in the region. This market, which includes medications that help manage blood glucose levels, is experiencing a positive impact from the COVID-19 pandemic, as diabetes is a significant risk factor for severe COVID-19 outcomes. The high prevalence of diabetes, exacerbated by rising obesity rates and genetic predispositions, has led to a substantial demand for DPP-4 inhibitors. These medications are particularly beneficial as they enhance insulin and GLP-1 secretion, offering a dual advantage in managing diabetes and mitigating COVID-19 complications. The market is characterized by a few major players, such as Eli Lilly, AstraZeneca, Merck, Boehringer Ingelheim, and Novartis, alongside regional manufacturers.

Saudi Arabia holds a significant share of the market, with a notable prevalence of diabetes among its population. The Saudi government is actively working to improve healthcare access and quality, addressing the growing demand due to lifestyle diseases like diabetes and obesity. The market's growth is further supported by the introduction of new drugs and therapies, such as Tradjenta, which is expected to register a high growth rate. The market's expansion is also influenced by government policies and initiatives aimed at reducing diabetes-related complications and promoting healthier lifestyles. As the region continues to grapple with the diabetes epidemic, the DPP-4 inhibitors market is expected to see sustained growth, offering new treatment options and improving patient outcomes.

Explore More

Middle East And Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug

      1. 2.1.1 Januvia (Sitagliptin)

      2. 2.1.2 Onglyza (Saxagliptin)

      3. 2.1.3 Tradjenta (Linagliptin)

      4. 2.1.4 Vipidia/Nesina (Alogliptin)

      5. 2.1.5 Galvus (Vildagliptin)

      6. 2.1.6 Other Drugs

    2. 2.2 Geography

      1. 2.2.1 Saudi Arabia

      2. 2.2.2 Iran

      3. 2.2.3 Egypt

      4. 2.2.4 Oman

      5. 2.2.5 South Africa

      6. 2.2.6 Rest of Middle East and Africa

Middle East And Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size FAQs

The Middle East And Africa Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 758.32 million in 2024 and grow at a CAGR of 3.60% to reach USD 893.21 million by 2029.

In 2024, the Middle East And Africa Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 758.32 million.

MEA DPP4 Drugs Market Report Snapshots

MEA DPP4 Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)